Pharmacologic action of isoxsuprine in cutaneous and myocutaneous flaps.
The therapeutic effects of isoxsuprine on skin capillary blood flow and viability were studied in arterial buttock flaps, latissimus dorsi myocutaneous flaps, and random skin flaps in pigs. It was observed that parenteral isoxsuprine increased capillary blood flow to the skin of arterial buttock flaps and the skin and muscle of latissimus dorsi myocutaneous flaps in a dose-response manner, with a maximum vascular effect observed at 1.0 mg/kg. However, this maximum effective dose of isoxsuprine did not have any significant effect on skin viability in the cutaneous and myocutaneous flaps compared with the control. Examination of the distribution of capillary blood flow within the flaps at varying distances from the pedicle revealed that isoxsuprine did not increase capillary blood flow or perfusion distance in the distal portion of the skin of arterial buttock flaps, latissimus dorsi myocutaneous flaps, and random skin flaps. The increased capillary blood flow as a result of isoxsuprine treatment was limited only to the arterial portion of the arterial buttock flaps and latissimus dorsi flaps. Therefore, it is concluded that isoxsuprine alone is not effective in augmentation of skin viability in cutaneous and myocutaneous flaps. The pharmacologic action of isoxsuprine on the vasculature in the skin and muscle of flaps was also discussed.
D000818:Animals; D001794:Blood Pressure; D001831:Body Temperature; D002196:Capillaries; D002302:Cardiac Output; D004305:Dose-Response Relationship, Drug; D005456:Fluorescent Dyes; D007273:Injections, Intramuscular; D007556:Isoxsuprine / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D012867:Skin / Q000098:blood supply; D013524:Surgical Flaps; D013552:Swine
D005456:Fluorescent Dyes; D007556:Isoxsuprine